Vol. 288, Issue 2, 710-713, February 1999

Novel Antipsychotic-Like Effects on Prepulse Inhibition of Startle Produced by a Neurotensin Agonist¹

David Feifel, Tammi L. Reza, David J. Wustrow and M. Duff Davis

Department of Psychiatry, University of California, San Diego, La Jolla, California (D.F., T.L.R.), and Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co., Ann Arbor, Michigan (D.J.W., D.D.)

Agonists of the neuropeptide neurotensin have been proposed as potential novel antipsychotics based on their ability to modulate neurotransmission in brain regions associated with schizophrenia. To test this hypothesis, we examined the effects of a neurotensin mimetic with improved metabolic stability in an animal model with strong predictive validity for antipsychotic activity. Subcutaneous injections of PD149163, a reduced amide neurotensin(8-13) mimetic, significantly antagonized the reduction of prepulse inhibition (PPI) of the rat startle reflex produced by amphetamine and by the phencyclidine analog dizocilpine. PD149163 had no significant effect on baseline PPI or on baseline startle amplitude and did not antagonize the reduction of PPI produced by the direct dopamine agonist apomorphine. These findings suggest that PD149163 has novel antipsychotic-like properties that are distinct from known members of both the "typical" and "atypical" families of antipsychotics.